Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 12/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.35 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23075920 | 0.82 | RIPK1 (0.48) | MAP3K14RIPK1GRM5PDE3BPDE3A | |
| SCHEMBL25586411 | 0.81 | GRM5 (0.40) | MAP3K14RIPK1GRM5PDE3BPDE3A | |
| SCHEMBL25586388 | 0.81 | NPC1 (0.49) | RIPK1GRM5NPC1RAB9A | |
| SCHEMBL23076327 | 0.80 | RIPK1 (0.48) | RIPK1GRM5NPC1PKMRAB9A | |
| SCHEMBL25586520 | 0.78 | RIPK1 (0.47) | RIPK1 | |
| SCHEMBL30387134 | 0.77 | RIPK1 (0.47) | RIPK1GRM5 | |
| SCHEMBL25584836 | 0.77 | RIPK1 (0.47) | RIPK1GRM5 | |
| SCHEMBL23085749 | 0.77 | MAP3K14 (0.37) | MAP3K14GRM5PDE3BPDE3AACACB | |
| SCHEMBL23081626 | 0.77 | MAP3K14 (0.46) | MAP3K14RIPK1 | |
| SCHEMBL23085558 | 0.76 | GABRA1 (0.41) | MAP3K14RIPK1GRM5PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167129-A1 | HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167129-A1 | HETEROCYCLIC AMIDE FOR INHIBITING RIP1 KINASE AND USES THEREOF | RIPK1, RIPK3, RIPK4 | MAP3K14 54/4885RIPK1 1/4885GRM5 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.